Johnson & Johnson wants to pay $6.5 billion to settle its talc ovarian cancer lawsuitsByBruce GilPublishedMay 1, 2024
Novo Nordisk earnings are coming during a weight loss drugs sales surge. Here are 3 things to watchByBruce GilUpdatedMay 1, 2024
Weight loss drugs are so hot that Eli Lilly is expecting $2 billion more in sales this yearByBruce GilPublishedApril 30, 2024
AbbVie's newer drugs are offsetting losses of the world's once best-selling medicationByBruce GilPublishedApril 26, 2024
Merck and Bristol-Myers Squibb are bracing to lose their most lucrative patentsByBruce GilUpdatedApril 25, 2024
Drug sales keep beating Wall Street's expectations and boosting some pharma stocksByBruce GilPublishedApril 25, 2024
Fake Ozempic sites, more Zepbound shortage, and J&J 's sales miss: Pharma news roundupByBruce GilPublishedApril 19, 2024
Even more doses of Eli Lilly's Zepbound and Mounjaro are officially in a shortage, FDA saysByBruce GilPublishedApril 17, 2024
Eli Lilly's weight loss drug Zepbound could help treat sleep apnea — paving a way to Medicare coverageByBruce GilUpdatedApril 17, 2024
